Repurposing FDA-approved drugs for SARS-CoV-2 through an ELISA-based screening for the inhibition of RBD/ACE2 interaction

Protein Cell. 2020 Nov 18;1-6. doi: 10.1007/s13238-020-00803-w. Online ahead of print.
No abstract available

Publication types

  • Letter